Renal anemia is a common complication of chronic kidney disease (CKD). Although there are treatments for the disease, physicians, patients, and healthcare systems have concerns about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of such therapies as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). The renal anemia therapy market will expand over the 2019-2029 study period, fueled by increasing prevalence and demand for new drugs that can effectively, safely, and conveniently control the disease. The launches of several hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected during the study period; of this drug class, roxadustat was the first to launch (in Japan in 2019). Although these new therapies offer advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.